Updates in the pharmacotherapeutic management of familial hypercholesterolemia (FH): present and emerging treatment options
Cost: FreeView Offer chevron_right
Familial hypercholesterolemia (FH), also known as type II hyperlipoproteinemia, is an autosomal dominant disorder characterized by elevated plasma LDL-C levels in the absence of hypertriglyceridemia (or if triglycerides are elevated, they are so independently of FH).
After completing Updates in the pharmacotherapeutic management of familial hypercholesterolemia (FH): present and emerging treatment options physicians will better be able to:
- Describe the pathophysiology and genetics of FH such that they might inform treatment mechanisms
- Describe presently available and emerging treatment options for FH and apply them to patient cases
- Evaluate a FH treatment plan and suggest modifications for improvement
- Describe clinical and logistical challenges associated with treating and educating patients with FH
Target Audience: Cardiology and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in cardiology; and any other clinicians with an interest in FH.